Anomer Bio

Anomer Bio is a London-based biotech startup focused on advancing glycoscience by developing synthetic monosaccharides aimed at enhancing immune responses and addressing complex health challenges. Founded in 2024, Anomer Bio is dedicated to pioneering innovations in biotechnology, particularly in the realm of synthetic sugars. As of August 2025, the company successfully completed its first funding deal, receiving seed investment from SOSV. The firm is headquartered in London, UK, and was established by a team passionate about leveraging glycoscience to create impactful solutions in immunology.

Glyconix specializes in the development of synthetic monosaccharides designed to modify immune responses by altering how sugars interact with proteins and cells. The core product offerings leverage machine learning approaches to model cellular processing of sugars, enabling the creation of synthetic sugars that target previously unmodifiable glycan structures. These innovations aim to address critical challenges in immunology, potentially leading to therapeutic applications in autoimmune diseases, cancer treatment, and other immune-related conditions. Glyconix's customer base includes pharmaceutical companies and research institutions engaged in drug development and immunotherapy, primarily operating in North America and Europe, where there is a strong demand for advanced glycoscience solutions.

Glyconix generates revenue through strategic partnerships and collaborations with pharmaceutical companies and research entities, facilitating the adoption of their synthetic sugar products in drug development processes. Transactions are structured around collaborative agreements, which may include upfront payments, milestone payments, and royalties based on the success of the developed therapies. Their flagship products, designed for specific immunological applications, are integrated into the clients' drug development pipelines, which allows for tailored pricing models specific to each partnership. Such agreements enable Glyconix to maintain a steady revenue stream while facilitating the advancement of innovative therapies in immune modulation.

With the recent seed funding raised in August 2025, Anomer Bio plans to accelerate its research and development efforts, focusing on the introduction of new synthetic sugars designed for specific therapeutic applications in immunology. The company aims to expand its market presence in North America and Europe, targeting collaborations with additional pharmaceutical and biotech firms by the end of 2026. The funding will support the development of new product lines and enhance their marketing strategies to broaden their reach within the drug development sector.